The HIV+Hepatitis Policy Institute strongly supports Oregon Senate Bill 560, which would require health insurers and health care service contractors to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums.
The HIV+Hepatitis Policy Institute strongly supports The PBM Accountability Study Act (HR 1829), which would require the Government Accountability Office to provide a comprehensive report to Congress on the ways in which PBMs influence the pricing of pharmaceuticals, impede competition, use rebates and also provide recommendations on ways to lower prescription drug costs.
The HIV+HEP Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support Senate Bill 94, which would require health insurers and health care service contractors to accept and count payments made on behalf of patients towards deductibles and out‐of‐pocket maximums.
We, the undersigned 124 organizations, on behalf of millions of patients and American consumers who live with complex conditions such as HIV, autoimmune diseases, cancer, diabetes, lupus, multiple sclerosis, and hepatitis, write to congratulate you on becoming Secretary and express our deep commitment and interest in working with you, the Department of Health and Human Services (HHS), and the Biden administration to implement policies and measures that improve prescription drug affordability and access for the American people.
The HIV+Hepatitis Policy Institute is a national HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support House Bill 4353, which would require health insurers to accept and count payments made on behalf of patients for prescription drugs towards their deductible and out-of-pocket maximum.